Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

(Reuters) - Novo Nordisk (NYSE:NVO) said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” fourth quarter 2024 ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

ByInvesting.com • Oct 20, 2021 Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris (Reuters) - Cigna Corp (NYSE:CI)'s pharmacy benefit unit said on Wednesday it will prefer ...